Press Releases - Archive



Shareholder Tools


 
Press Releases - Archive
Date Title and Summary View
Aug 21, 2017 SOUTH SAN FRANCISCO, Calif., Aug. 21, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that on August 18, 2017, the compensation committee of the Company's board of dir...
Aug 8, 2017 SOUTH SAN FRANCISCO, Calif., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that the Company will be presenting at the 2017 Wedbush PacGrow Healthcare Confer...
Aug 3, 2017 -- Plazomicin granted Breakthrough Therapy designation -- -- C-Scape Phase 1 study underway to evaluate orally-administered antibacterial candidate for infections due to ESBL-producing Enterobacteriaceae -- -- Conference call today at 4:30 p.m. Eastern Tim...
Jul 27, 2017 SOUTH SAN FRANCISCO, Calif., July 27, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company discovering and developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that it will report its second quarter financial results on Thurs...
Jul 25, 2017 -- CARB-X funding highlights Achaogen's innovative LpxC program and urgent need for gram-negative antibiotics -- -- Awarded $3.2 million over 12 months, and potentially up to a total award of $11.4 million -- SOUTH SAN FRANCISCO, Calif., July 25, 2017 (GLO...
Jul 24, 2017 SOUTH SAN FRANCISCO, Calif., July 24, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that on July 20, 2017, the compensation committee of the Company's board of dir...
Jul 13, 2017 SOUTH SAN FRANCISCO, Calif., July 13, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced the appointment of Dr. Karen Bernstein, Co-Founder and Chairman of BioCentury ...
Jun 22, 2017 SOUTH SAN FRANCISCO, Calif., June 22, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that on June 20, 2017, the compensation committee of the Company's board of...
Jun 5, 2017 -- Oral presentations highlighted data from plazomicin Phase 3 EPIC and CARE clinical trials -- -- Newly-released in vitro data demonstrated potent activity of plazomicin against contemporary multidrug-resistant Enterobacteriaceae isolates -- NEW ORLEANS, June 05, 2017 (GLOBE NE...
Jun 1, 2017 -- Clinical trial to evaluate orally-administered beta-lactam/beta-lactamase inhibitor combination being developed for infections due to extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae -- -- Initiation of pivotal Phase 3 clinical trial in patients with compl...
Page:
1
... NextLast
= add release to Briefcase